Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial

Fig. 2

Distribution of estimated individual treatment effects and conditional average treatment effects within each quintile of estimated individual treatment effects. Shown are A the distribution of estimated individual treatment effects of PMX-HA on 28-day survival and B the conditional average treatment effects of PMX-HA within each quintile of estimated individual treatment effects. Higher treatment effects on 28-day survival are equivalent to higher absolute risk reduction of 28-day mortality. Both graphs visually point to the presence of heterogeneity in the effects of PMX-HA on 28-day survival in patients with sepsis. PMX-HA = Polymyxin B Hemadsorption

Back to article page

Critical Care

ISSN: 1364-8535